ATE386800T1 - Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten - Google Patents
Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheitenInfo
- Publication number
- ATE386800T1 ATE386800T1 AT94911633T AT94911633T ATE386800T1 AT E386800 T1 ATE386800 T1 AT E386800T1 AT 94911633 T AT94911633 T AT 94911633T AT 94911633 T AT94911633 T AT 94911633T AT E386800 T1 ATE386800 T1 AT E386800T1
- Authority
- AT
- Austria
- Prior art keywords
- vaccines
- peptide
- treatment
- diseases
- signal sequence
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 3
- 108010076504 Protein Sorting Signals Proteins 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000007523 nucleic acids Chemical group 0.000 title 1
- 210000003660 reticulum Anatomy 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 241000700618 Vaccinia virus Species 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/77—Ovalbumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3290293A | 1993-03-17 | 1993-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE386800T1 true ATE386800T1 (de) | 2008-03-15 |
Family
ID=21867477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT94911633T ATE386800T1 (de) | 1993-03-17 | 1994-03-17 | Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten |
Country Status (8)
Country | Link |
---|---|
US (3) | US5733548A (de) |
EP (1) | EP0689551B1 (de) |
JP (2) | JPH08508252A (de) |
AT (1) | ATE386800T1 (de) |
AU (1) | AU692152B2 (de) |
CA (1) | CA2158455C (de) |
DE (1) | DE69435075T2 (de) |
WO (1) | WO1994021680A1 (de) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69332485T2 (de) * | 1992-08-11 | 2003-11-13 | Harvard College | Immunmodulierende peptide |
US6696061B1 (en) | 1992-08-11 | 2004-02-24 | President And Fellows Of Harvard College | Immunomodulatory peptides |
FR2709309B1 (fr) * | 1993-08-25 | 1995-11-10 | Centre Nat Rech Scient | Compositions cellulaires, préparation et utilisations thérapeutiques. |
WO1997026911A1 (en) | 1996-01-29 | 1997-07-31 | Georgetown University | Malaria vaccine based upon the addition of a msa1 peptide |
US20060002959A1 (en) * | 1996-11-14 | 2006-01-05 | Government Of The United States | Skin-sctive adjuvants for transcutaneous immuization |
US5980898A (en) * | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
US6797276B1 (en) * | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
AU7724398A (en) * | 1997-06-06 | 1998-12-21 | Regents Of The University Of California, The | A melanoma associated antigen, t cell epitopes thereof and methods of using sa me |
US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
US6994851B1 (en) | 1997-07-10 | 2006-02-07 | Mannkind Corporation | Method of inducing a CTL response |
FR2766091A1 (fr) * | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
US6183746B1 (en) | 1997-10-09 | 2001-02-06 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
US20040258703A1 (en) * | 1997-11-14 | 2004-12-23 | The Government Of The Us, As Represented By The Secretary Of The Army | Skin-active adjuvants for transcutaneous immunization |
US20080050367A1 (en) * | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7790856B2 (en) * | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US6787523B1 (en) * | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US7588766B1 (en) * | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
US20030138808A1 (en) * | 1998-02-19 | 2003-07-24 | Simard John J.L. | Expression vectors encoding epitopes of target-associated antigens |
US20050059802A1 (en) * | 1998-04-07 | 2005-03-17 | Neuralab Ltd | Prevention and treatment of amyloidogenic disease |
WO1999064583A2 (en) * | 1998-06-12 | 1999-12-16 | The Government Of The United States Of America, Represented By The Secretary, Department Of Healt H And Human Services | Compositions and methods for modulating proteolytic degradation of intracellular targets |
JP4932086B2 (ja) * | 1999-04-08 | 2012-05-16 | インターセル ユーエスエイ、インコーポレイテッド | 経皮的免疫のための乾燥製剤 |
KR100922809B1 (ko) * | 1999-05-06 | 2009-10-21 | 웨이크 포리스트 유니버시티 | 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법 |
WO2000068379A1 (en) * | 1999-05-07 | 2000-11-16 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for treating tumors using antiangiogenic compounds |
US20050100928A1 (en) * | 1999-09-16 | 2005-05-12 | Zycos Inc., A Delaware Corporation | Nucleic acids encoding polyepitope polypeptides |
AU5741001A (en) * | 2000-04-28 | 2001-11-12 | Ctl Immunotherapies Corp | Epitope synchronization in antigen presenting cells |
US6861234B1 (en) | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
US20030215425A1 (en) * | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
PE20020574A1 (es) * | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
ES2310201T3 (es) * | 2001-02-13 | 2009-01-01 | Government Of The United States Of America, As Represented By The Secretary Of The Army | Vacuna para inmunizacion transcutanea contra la diarrea de los viajeros. |
WO2003063770A2 (en) * | 2001-11-07 | 2003-08-07 | Mannkind Corporation | Expression vectors encoding epitopes of target-associated antigens and methods for their design |
WO2003064609A2 (en) * | 2002-01-29 | 2003-08-07 | Aventis Pasteur, Ltd. | Targeted immunogens |
MY139983A (en) * | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
JP2006503914A (ja) * | 2002-10-21 | 2006-02-02 | エムジーアイ ファーマ バイオロジックス インコーポレイテッド | ヒトパピローマウイルス媒介性疾患を治療するための組成物および方法 |
BRPI0407058A (pt) * | 2003-02-01 | 2006-01-17 | Neuralab Ltd | Métodos de profilaxia e de tratamento de uma doença, composição farmacêutica, e, uso de um fragmento |
TWI306458B (en) * | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
EP1838854B1 (de) * | 2004-12-15 | 2012-10-31 | Janssen Alzheimer Immunotherapy | Antikörper, die Amyloid-Peptide erkennen |
WO2006066171A1 (en) * | 2004-12-15 | 2006-06-22 | Neuralab Limited | Amyloid βετα antibodies for use in improving cognition |
CA2590337C (en) * | 2004-12-15 | 2017-07-11 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
AU2005321940B2 (en) * | 2004-12-29 | 2012-04-19 | Mannkind Corporation | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
BRPI0620755A2 (pt) * | 2005-12-27 | 2011-11-22 | Obetech Llc | adenovìrus adipogênicos como um biomarcardor para doenças |
US8784810B2 (en) * | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US8003097B2 (en) * | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
CA2684323A1 (en) * | 2007-04-18 | 2008-10-30 | Janssen Alzheimer Immunotherapy | Prevention and treatment of cerebral amyloid angiopathy |
ES2498040T3 (es) | 2007-07-27 | 2014-09-24 | Janssen Alzheimer Immunotherapy | Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados |
JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
CN101998965B (zh) | 2007-11-01 | 2014-03-12 | 安斯泰来制药有限公司 | 免疫抑制性多肽与核酸 |
US20090117123A1 (en) * | 2007-11-02 | 2009-05-07 | National Health Research Institutes | Immunopeptides of hpv e6 and e7 proteins |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2549504B2 (ja) * | 1984-12-21 | 1996-10-30 | ア−ス製薬株式会社 | Dna塩基配列、ポリペプチド分泌発現ベクター及び形質転換微生物 |
GB8629153D0 (en) * | 1986-12-05 | 1987-01-14 | Ciba Geigy Ag | Hybrid proteins |
US4872264A (en) * | 1988-01-11 | 1989-10-10 | Labounty Roy E | Heavy duty plate shear |
SE8802939D0 (sv) * | 1988-08-19 | 1988-08-19 | Kabigen Ab | A method for the production and isolation of a fusion protein in eukaryotic cells |
US5098833A (en) * | 1989-02-23 | 1992-03-24 | Genentech, Inc. | DNA sequence encoding a functional domain of a lymphocyte homing receptor |
EP0600930B1 (de) * | 1991-08-02 | 2002-10-02 | FAUSTMAN, Denise L. | Diagnose und behandlung von autoimmunkrankheiten |
WO1994004557A1 (en) * | 1992-08-11 | 1994-03-03 | President And Fellows Of Harvard College | Immunomodulatory peptides |
US6696061B1 (en) * | 1992-08-11 | 2004-02-24 | President And Fellows Of Harvard College | Immunomodulatory peptides |
-
1994
- 1994-03-17 WO PCT/US1994/002897 patent/WO1994021680A1/en active IP Right Grant
- 1994-03-17 AU AU64107/94A patent/AU692152B2/en not_active Ceased
- 1994-03-17 JP JP6521237A patent/JPH08508252A/ja not_active Withdrawn
- 1994-03-17 CA CA002158455A patent/CA2158455C/en not_active Expired - Fee Related
- 1994-03-17 DE DE69435075T patent/DE69435075T2/de not_active Expired - Lifetime
- 1994-03-17 EP EP94911633A patent/EP0689551B1/de not_active Expired - Lifetime
- 1994-03-17 AT AT94911633T patent/ATE386800T1/de not_active IP Right Cessation
-
1995
- 1995-06-05 US US08/464,318 patent/US5733548A/en not_active Expired - Lifetime
- 1995-06-05 US US08/461,566 patent/US5856187A/en not_active Expired - Lifetime
- 1995-06-06 US US08/471,341 patent/US5846540A/en not_active Expired - Lifetime
-
2005
- 2005-07-06 JP JP2005197523A patent/JP2005341969A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DE69435075T2 (de) | 2009-02-19 |
WO1994021680A1 (en) | 1994-09-29 |
US5846540A (en) | 1998-12-08 |
US5733548A (en) | 1998-03-31 |
AU6410794A (en) | 1994-10-11 |
JP2005341969A (ja) | 2005-12-15 |
DE69435075D1 (de) | 2008-04-03 |
CA2158455A1 (en) | 1994-09-29 |
US5856187A (en) | 1999-01-05 |
AU692152B2 (en) | 1998-06-04 |
CA2158455C (en) | 2003-05-27 |
JPH08508252A (ja) | 1996-09-03 |
EP0689551A1 (de) | 1996-01-03 |
EP0689551B1 (de) | 2008-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE386800T1 (de) | Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten | |
LV5288A3 (lv) | Nukleinskabes fragments kurs kode cilveka proapolipoproteinu A-1 | |
DE69840230D1 (de) | Polypeptide mit prolyldipeptidylaminopeptidase-aktivität und dafür kodierende nukleinsäuren | |
ATE310090T1 (de) | Gereinigte coprinus laccasen und nukleinsäuren welche dafür kodieren | |
DE69930955D1 (de) | Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren | |
DE69534600D1 (de) | Nukleotid- und aminosäuresequenzen der gene des hüllproteins 1 und des kernproteins von hepatitis c virus | |
ATE338113T1 (de) | Transferrin-rezeptor gene von haemophilus | |
HUP0100267A2 (hu) | Helicobacter pylori eredetű nukleinsav- és aminosav-szekvenciák és a megfelelő nukleinsavakat vagy peptideket tartalmazó vakcina-készítmények | |
DK0791063T3 (da) | Bærerprotein med adjuvansvirkning, immunogent kompleks omfattende det, fremgangsmåde til fremstilling deraf, nukleotidsekvens og vaccine | |
NZ335633A (en) | Production of recombinant H. pylori polypeptides for treatment and diagnosis of H. pylori related diseases | |
DE60326449D1 (de) | Chimere human papilloma virus 16 l1 proteine, welche ein l2 peptid enthalten, damit hergestellte virus-ähnliche partikel und methode zur herstellung der partikel | |
DK27097A (da) | Minactivin og fremgangsmåde til fremstilling deraf | |
ATE278011T1 (de) | Human dnase ii | |
WO2000043419A3 (en) | Exocytosis pathway proteins and methods of use | |
MXPA05009954A (es) | Familia de proteinas secretadas. | |
WO2001036476A3 (en) | Ing2, an iaps associated cell cycle protein, compositions and methods of use | |
WO1999042586A3 (en) | Exo1 and exo2, exocytotic proteins | |
WO2002064628A3 (en) | Isolated human transporter proteins nucleic acids and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |